^
Association details:
| Biomarker: | EGFR mutation + MET amplification |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | c-MET inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer
Published date:
06/01/2023
Excerpt:
The patients with EGFR-mutant, MET-amplified lung cancer resistant to EGFR inhibitors showed definite response to single MET inhibitor...Single MET inhibition produced a short-lived response in EGFR-mutant and MET-amplified lung cancer. A further study of a novel combination therapy schedule is needed to achieve long-lasting efficacy and less toxicity.
DOI:
10.1038/s41416-023-02264-4
